Endothelial ALK1 is a therapeutic target to block metastatic dissemination of breast cancer

Cancer Research

Volumn 75, Issue 12, 2015, Pages 2445-2456

  Cunha, Sara I ^a,b   Bocci, Matteo ^c   Lövrot, John ^b   Eleftheriou, Nikolas ^c   Roswall, Pernilla ^b   Cordero, Eugenia ^c   Lindström, Linda ^b   Bartoschek, Michael ^c   Haller, B Kristian ^b   Pearsall, R Scott ^d   Mulivor, Aaron W ^d   Kumar, Ravindra ^d   Larsson, Christer ^c   Bergh, Jonas ^b   Pietras, Kristian ^b,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d Acceleron Pharma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; DOCETAXEL; ENDOTHELIAL ACTIVIN RECEPTOR LIKE KINASE 1; IMMUNOGLOBULIN G; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAP 041; UNCLASSIFIED DRUG; ACTIVIN RECEPTOR 2; ACVRL1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOLOGY; BREAST CARCINOMA; CANCER PROGNOSIS; CASE CONTROL STUDY; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG IDENTIFICATION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; C57BL MOUSE; ENDOTHELIUM; ENZYMOLOGY; FEMALE; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ACTIVIN RECEPTORS, TYPE II; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; ENDOTHELIUM; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS;

EID: 84941736038     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3706     Document Type: Article

References (33)

1. Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC. Past, present, and future challenges in breast cancer treatment. J Clin Oncol 2014;32:1979-86.
2. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organspecific colonization. Nat Rev Cancer 2009;9:274-84.
3. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med 2008;359:2814-23.
4. Walters S, Maringe C, Butler J, Rachet B, Barrett-Lee P, Bergh J, et al. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. Br J Cancer 2013;108:1195-208.
5. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49.
6. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74.
7. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol 1998;184:119-22.
8. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
9. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
10. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
11. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13.
12. Kumler I, Christiansen OG, Nielsen DL. A systematic review of bevacizumab efficacy in breast cancer. Cancer Treat Rev 2014;40:960-73.
13. Mackey JR, Kerbel RS, Gelmon KA, McLeod DM, Chia SK, Rayson D, et al. Controlling angiogenesis in breast cancer: a systematic review of antiangiogenic trials. Cancer Treat Rev 2012;38:673-88.
14. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31.
15. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Acceleratedmetastasis after short-term treatmentwith a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
16. Anderberg C, Cunha SI, Zhai Z, Cortez E, Pardali E, Johnson JR, et al. Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. J Exp Med 2013;210:563-79.
17. Cunha SI, Pietras K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 2011;117:6999-7006.
18. Cunha SI, Pardali E, Thorikay M, Anderberg C, Hawinkels L, Goumans MJ, et al. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med 2010;207:85-100.
19. Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, Monnell TE, et al. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther 2010;9:379-88.
20. Hu-Lowe DD, Chen E, Zhang L, Watson KD, Mancuso P, Lappin P, et al. Targeting activin receptor-like kinase 1 (ALK1) inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res 2011;71:1362-73.
21. Lindstrom L, Jauhiainen A, Wilking U, Foukakis T, Åström G, Czene K, et al. Abstract P6-06-17: gene signature model predicts metastatic onset better than standard clinical markers-Nested case-control design uniquely enables enrichment for biologically relevant features. Cancer Res 2013;73 Suppl 24:P6-06-17.
22. House MG, Schulick RD. Endocrine tumors of the pancreas. Curr Opin Oncol 2006;18:23-9.
23. Fluck MM, Schaffhausen BS. Lessons in signaling and tumorigenesis from polyomavirusmiddle T antigen. Microbiol Mol Biol Rev 2009;73:542-63.
24. Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, et al. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res 2014;20:480-9.
25. Necchi A, Giannatempo P, Mariani L, Fare E, Raggi D, Pennati M, et al. PF-03446962, a fully-human monoclonal antibody against transforming growth-factor beta (TGFbeta) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. Invest New Drugs 2014;32:555-60.
26. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.
27. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
28. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008;319:195-8.
29. Wolf MJ, Hoos A, Bauer J, Boettcher S, Knust M, Weber A, et al. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell 2012;22:91-105.
30. Branco-Price C, Zhang N, Schnelle M, Evans C, Katschinski DM, Liao D, et al. Endothelial cell HIF-1alpha and HIF-2alpha differentially regulate metastatic success. Cancer Cell 2012;21:52-65.
31. Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and prometastatic factor in human cancer. Biochim Biophys Acta 2007;1775:21-62.
32. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61:3369-72.
33. Ponten F, Jirstrom K, Uhlen M. The Human Protein Atlas-a tool for pathology. J Pathol 2008;216:387-93.